Clinical Trial Update: A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of elsubrutinib and upadacitinib alone or in combination in moderately to severely active systemic lupus erythemato…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Elsubrutinib (elsubrutinib)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 2 | Status: COMPLETED | Results posted: 2023-07-21